John Meletis

Soluble receptor activator of nuclear factor κB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

Evangelos Terpos, Richard Szydlo, Jane F. Apperley et al. · Blood · 2003 · 413 citations · Full text

Medicine, Cancer Biology, Oncology +15

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations

Panagiotis Diamantopoulos, Maria Michael, Efthymia Bazanis et al. · Virology Journal · 2012 · 243 citations · Full text

Life Sciences, Hematology, Immunology +15

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

Evangelos Terpos, Dimitrios Christoulas, Eirini Katodritou et al. · International Journal of Cancer · 2011 · 182 citations · Full text

Medicine, Hematology, Oncology +17

Cardiac status in well‐treated patients with thalassemia major

Athanasios Aessopos, Dimitrios Farmakis, Antonia Hatziliami et al. · European Journal Of Haematology · 2004 · 179 citations · Full text

Medicine, Cardiology, Hematology +10

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care

Theodoros P. Vassilakopoulos, Gerassimos A. Pangalis, Andreas Katsigiannis et al. · The Oncologist · 2012 · 124 citations · Full text

Medicine, Oncology, Pharmacotherapy +15